secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001558370-23-016220
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences receives generic challenge notices for WAKIX from Novugen and Lupin
--------------------------------------------------------------------------------

- Novugen Pharma and Lupin Ltd. filed ANDAs seeking FDA approval to market generic pitolisant (WAKIX) before patent expiry.
- Paragraph IV notices challenge U.S. Patents 8,486,947 & 8,207,197, expiring Sept 2029 and Mar 2030 respectively.
- Patent 8,354,430 (expiring Feb 2026) is not challenged in the notices.
- Company states it will vigorously defend its intellectual property rights for WAKIX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023016220/0001558370-23-016220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023016220/hrmy-20230928x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer